HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction

Phase 2BGE-102Positive

AI Analysis

Summary

BioAge Labs has dosed the first participant in the Phase 2 QUELL-CV trial of BGE-102, a novel oral NLRP3 inhibitor developed with HitGen's DEL technology platform for cardiovascular risk reduction.

Clinical Trial Data

Phase

Outcome Details

first participant dosed

Importance:6/10

Sentiment:

0.60

NLRP3 inhibitorcardiovascularoral drugbrain-penetrantDEL technologyQUELL-CV trial

Related Companies

$BIOA

Read the original article

Published by PR Newswire Biotech on July 14, 2026 1:30 PM

Read Original